Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ATx08-001: Phase II data

A double-blind, U.S. Phase II trial in 61 patients showed that twice-daily 2.5 and 7.5 mg oral

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE